Lake Street Capital reiterated coverage on PAVmed with a new price target
$PAVM
Medical/Dental Instruments
Health Care
Lake Street Capital reiterated coverage of PAVmed with a rating of Buy and set a new price target of $9.00 from $5.00 previously
Save time and jump to the most important pieces.
Campaign will coincide with Esophageal Cancer Awareness Month and will be featured at the upcoming Digestive Disease Week (DDW) Conference NEW YORK, March 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced a campaign, entitled "Embrace the Future", designed to showcase its groundbreaking EsoCheck® Esophageal Cell Collection Device, with Collect+Protect™ Technology, to gastroenterologists and the broader medical community. The campaign will coincide with Esophageal Cancer Awareness Month this April and will be prominently featur
Lucid processed record test volume, saw rapid initial uptake in concierge medicine contracts, and secured first commercial insurance coverage policies Veris Health secured financing to resume advancement of implantable physiological monitor through FDA clearance and commercial launch PAVmed completed debt restructuring and Lucid deconsolidation to regain Nasdaq compliance and strengthen balance sheet Conference call and webcast to be held today, March 25th, at 8:30 AM EDT NEW YORK, March 25, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital
Processed a record 4,042 EsoGuard tests in 4Q24, a 45% sequential and 84% annual increase Recognized EsoGuard revenue of $1.2 million in 4Q24 New sales channel generated over 20 new cash-pay concierge medicine contracts Secured first agreement to pay for EsoGuard under state biomarker legislation Conference call and webcast to be held today, March 24th at 8:30 AM EDT NEW YORK, March 24, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) ("PAVmed"), today provided a business update for the Company and reported financial results for the four
3 - PAVmed Inc. (0001624326) (Issuer)
4 - PAVmed Inc. (0001624326) (Issuer)
4 - PAVmed Inc. (0001624326) (Issuer)
Efforts include appointment of seasoned biotech investor Sundeep Agrawal, M.D. to board to replace departing directors NEW YORK, Sept. 16, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that, as part of its efforts to regain compliance with Nasdaq's listing requirements, Lucid Diagnostics (NASDAQ:LUCD) ("Lucid") will be deconsolidated from PAVmed's financial statements. As a result, PAVmed will no longer report consolidated financials reflecting Lucid's operating losses. PAVmed's holdings of Lucid common stock remain
Final closing yields total gross proceeds of $29.8 million from offering Mr. Matheis serves as President and CEO of Sentara Health, one of the largest not-for-profit integrated health systems in the U.S., which encompasses hospitals, a physician group, and an affiliated health plan NEW YORK, May 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the Company has closed a Series B-1 Preferred Stock offering led by one of the Company's long-time institutional investors, with gross proceeds of $11.6 million, bringing
The incubator, PMX, and medical device firm Hatch Medical, execute joint venture agreement to complete their development and commercialization, starting with PortIO NEW YORK, March 21, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has launched a wholly owned incubator, PMX, to complete development and commercialization of existing portfolio technologies, including the PortIO™ Implantable Intraosseous Vascular Access Device ("PortIO"), EsoCure™ Esophageal Ablation Device ("EsoCure"), and CarpX® Minimally Inva
SC 13G - PAVmed Inc. (0001624326) (Subject)
SC 13G - PAVmed Inc. (0001624326) (Subject)
SC 13G - PAVmed Inc. (0001624326) (Subject)
Cantor Fitzgerald initiated coverage of PAVmed with a rating of Overweight and set a new price target of $8.00
Lake Street Capital reiterated coverage of PAVmed with a rating of Buy and set a new price target of $9.00 from $5.00 previously
8-K - PAVmed Inc. (0001624326) (Filer)
10-K - PAVmed Inc. (0001624326) (Filer)
8-K - PAVmed Inc. (0001624326) (Filer)
Lucid processed record test volume, saw rapid initial uptake in concierge medicine contracts, and secured first commercial insurance coverage policies Veris Health secured financing to resume advancement of implantable physiological monitor through FDA clearance and commercial launch PAVmed completed debt restructuring and Lucid deconsolidation to regain Nasdaq compliance and strengthen balance sheet Conference call and webcast to be held today, March 25th, at 8:30 AM EDT NEW YORK, March 25, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital
Processed a record 4,042 EsoGuard tests in 4Q24, a 45% sequential and 84% annual increase Recognized EsoGuard revenue of $1.2 million in 4Q24 New sales channel generated over 20 new cash-pay concierge medicine contracts Secured first agreement to pay for EsoGuard under state biomarker legislation Conference call and webcast to be held today, March 24th at 8:30 AM EDT NEW YORK, March 24, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) ("PAVmed"), today provided a business update for the Company and reported financial results for the four
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, March 11, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ), PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Tuesday, March 25, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the C